Catalog No.
FHD80940
Species reactivity
Human
Host species
Mouse
Isotype
IgG1, kappa
Clonality
Monoclonal
Conjugation
Unconjugated
Target
CD30L receptor, Ki-1 antigen, CD30, TNFRSF8, D1S166E, Tumor necrosis factor receptor superfamily member 8, Lymphocyte activation antigen CD30
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P28908
Applications
FCM
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4, 0.09% Sodium azide.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Clone ID
SAA1390
Design and functional characterization of a tetravalent NK cell-engaging bispecific antibody with enhanced half-life for CD30+ lymphoma., PMID:40487655
161Tb Radioimmunotherapy as a Treatment for CD30-Positive Lymphomas., PMID:40456588
Impact of CD3 expression on outcome in pediatric anaplastic large cell lymphoma., PMID:40444097
[Treatment challenges and optimal management of classical Hodgkin's lymphoma]., PMID:40425461
Anaplastic large cell lymphoma in children and adolescents., PMID:40351161
Dupilumab-associated lymphoproliferative disorders: a comprehensive review on clinicohistopathologic features and underlying mechanisms., PMID:40349527
HIV-Tat upregulates the expression of senescence biomarkers in CD4+ T-cells., PMID:40342418
Versatile intact LC-MS method for evaluating the drug-antibody ratio and drug load distribution of antibody-drug conjugates in human plasma., PMID:40267607
Paraneoplastic anti-SRP antibody positive immune-mediated necrotizing myopathy in a young female associated with lymphoma., PMID:40266663
Advancements in targeting CD30 for lymphoma therapy: a historical perspective and future directions., PMID:40227173
Allogeneic NK cells with a bispecific innate cell engager in refractory relapsed lymphoma: a phase 1 trial., PMID:40186077
Outcomes in patients with classic Hodgkin lymphoma refractory or intolerant to brentuximab vedotin and anti-PD-1 therapy: a real world analysis from 15 U.S. academic centers., PMID:40140364
SOHO State of the Art Updates and Next Questions | Latest Advances in the Management of Primary Mediastinal B-Cell Lymphoma., PMID:40121106
Generation of antagonistic biparatopic anti-CD30 antibody from an agonistic antibody by precise epitope determination and utilization of structural characteristics of CD30 molecule., PMID:39958564
Antibody-Drug Conjugates Targeting CD30 in T-Cell Lymphomas: Clinical Progression and Mechanism., PMID:39941862
Classic Hodgkin lymphoma: Pathobiological features that impact emerging therapies., PMID:39904647
Development of chimeric Nanobody-Granzyme B functionalized ferritin nanoparticles for precise tumor therapy., PMID:39880067
Correction to: Preclinical evaluation of 64Cu/177Lu‑labelled anti‑CD30 monoclonal antibody for theranostics in CD30‑positive lymphoma., PMID:39821664
Targeted immunotherapy in the treatment of childhood and adolescent classic Hodgkin lymphoma., PMID:39820376
Recent Advances in Understanding the Clinical Responses of Brentuximab Vedotin in Lymphoma and the Correlation with CD30 Expression., PMID:39802262
Advances in Novel Systemic Therapies for the Management of Cutaneous T Cell Lymphoma (CTCL)., PMID:39800801
Bispecific Antibodies for Lymphoid Malignancy Treatment., PMID:39796723
Phase II Open-Label Trial of Brentuximab Vedotin with Pembrolizumab in PD-1-Pretreated Metastatic Non-Small Cell Lung Cancer and Metastatic Cutaneous Melanoma., PMID:39786430
Preclinical evaluation of 64Cu/177Lu-labelled anti-CD30 monoclonal antibody for theranostics in CD30-positive lymphoma., PMID:39688699
When should we use it? The role of brentuximab vedotin in 2024., PMID:39644065
BV and beyond: how to incorporate novel agents into PTCL management., PMID:39644004
Brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine for advanced-stage classical Hodgkin lymphoma., PMID:39622165
Comparison of CD30L and OX40L Reveals CD30L as a Promising Therapeutic Target in Atopic Dermatitis., PMID:39589186
Brentuximab-Induced Acute Interstitial Nephritis: A Case Report., PMID:39588062
A case of karyomegalic interstitial nephritis without FAN1 mutations in the setting of brentuximab, ifosfamide, and carboplatin exposure., PMID:39543462
A Phase II Study of Acimtamig (AFM13) in Patients with CD30-Positive, Relapsed, or Refractory Peripheral T-cell Lymphomas., PMID:39531538
Severe subacute onset sensorimotor polyneuropathy associated with brentuximab vedotin treatment for refractory classical Hodgkin's lymphoma., PMID:39500584
Recurrent somatic mutations of FAT family cadherins induce an aggressive phenotype and poor prognosis in anaplastic large cell lymphoma., PMID:39478125
[Clinical study of immune-targeting combined with attenuated chemotherapy in the treatment of children with classic Hodgkin lymphoma]., PMID:39429083
CD30 influences germinal center B-cell dynamics and the expansion of IgG1-switched B cells., PMID:39420111
Understanding the Puzzle of Primary Breast Lymphoma: An Experience in a Tertiary Care Center in North India., PMID:39347303
The efficacy and safety of brentuximab vedotin for peripheral T-cell lymphoma: A systemic review and meta-analysis., PMID:39324259
Systemic treatments with monoclonal antibodies in mycosis fungoides and Sézary syndrome., PMID:39295883
Single-cell RNA sequencing of pediatric Hodgkin lymphoma to study the inhibition of T cell subtypes., PMID:39233904
[Antibody-Drug Conjugate for Treating Leukemia and Lymphoma-The Present Status, Problems, and Future Development]., PMID:39191681
Standardization of CD30 immunohistochemistry staining among three automated immunostaining platforms., PMID:39171823
Insights into uveitis from Brentuximab vedotin in refractory Hodgkin's lymphoma: a case report and brief review., PMID:39161379
Epigenetic agents plus anti-PD-1 reprogram the tumor microenvironment and restore antitumor efficacy in Hodgkin lymphoma., PMID:39093981
[Clinical experience of using brentuximab-vedotin as therapy in relapsed/refractory Hodgkin's lymphoma at Hospital Guillermo Grant Benavente, Concepción, Chile]., PMID:39093139
Subcellular expression of CD30 in cutaneous mastocytosis-An important factor for targeted treatment., PMID:39092659
Etoposide addition and brentuximab vedotin consolidation in first-line treatment of CD30-positive peripheral T-cell lymphoma: can we improve BV-CHP?, PMID:39067466
Brentuximab vedotin plus cyclophosphamide, doxorubicin, etoposide, and prednisone followed by brentuximab vedotin consolidation in CD30-positive peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 study., PMID:39067464
Landscape of clinical drug development of ADCs used for the pharmacotherapy of cancers: an overview of clinical trial registry data from 2002 to 2022., PMID:39060958
Non-Hodgkin's Anaplastic Large T-Cell Lymphoma: A Case Report., PMID:39050306
Phase I Trial of Brentuximab Vedotin Plus Cyclosporine in Relapsed/Refractory Hodgkin Lymphoma., PMID:39043499
For research use only. Not for human or drug use.
